Cost Is the Biggest Barrier to Ajovy Adherence

You've evaluated the patient. The diagnosis is clear — chronic or high-frequency episodic migraine. You've recommended Ajovy (Fremanezumab-vfrm), a proven CGRP inhibitor with strong clinical evidence and flexible dosing. The patient is on board. And then the pharmacy calls with the price.

At $690 to $1,019 per monthly dose without insurance, Ajovy can be a non-starter for patients without robust coverage. Even commercially insured patients may face high specialty tier copays of $100 to $300 or more per fill. The result? Prescriptions go unfilled, patients discontinue early, and migraine days remain uncontrolled.

As a prescriber, you're in a unique position to help. This guide covers the savings programs, assistance options, and workflow strategies that can help your patients actually afford the medication you prescribe.

What Your Patients Are Paying

Before diving into solutions, it helps to understand the cost landscape for Ajovy in 2026:

• Cash price (uninsured) — Approximately $690 to $1,019 per 225 mg/1.5 mL injection. Monthly dosing (225 mg) costs the same per unit as quarterly dosing (675 mg = three injections).
• Commercial insurance — Most plans cover Ajovy but place it on a specialty tier with higher cost-sharing. Prior authorization is nearly universal. Many plans require step therapy — patients must try and fail at least two preventive medications (typically Topiramate, Propranolol, or Amitriptyline) before approval.
• Medicare Part D — Limited coverage with significant cost-sharing, especially in the coverage gap ("donut hole"). The manufacturer copay card cannot be used by Medicare patients.
• Medicaid — Coverage varies by state. Most state Medicaid programs require prior authorization and step therapy. Cost to the patient is typically minimal if approved.

Understanding which bucket your patient falls into determines which savings pathway is most relevant.

Manufacturer Savings Programs

Ajovy Savings Card (Commercially Insured Patients)

Teva Pharmaceuticals offers the Ajovy Savings Card for eligible commercially insured patients. Key details:

• Patients may pay as little as $0 to $15 per prescription (monthly or quarterly)
• Maximum savings limits apply per prescription and per year
• Not available for patients on government insurance (Medicare, Medicaid, Tricare, VA)
• Patients can enroll at ajovy.com/savings or by calling 1-800-671-3674

Workflow tip: Have your front office or specialty pharmacy coordinator provide Ajovy Savings Card enrollment information at the time of prescribing — before the patient hits the pharmacy and sees the full price. Proactive enrollment prevents sticker shock and improves fill rates.

Teva Cares Foundation Patient Assistance Program (PAP)

For uninsured or underinsured patients who cannot afford Ajovy, the Teva Cares Foundation offers a patient assistance program that provides the medication at no cost:

• Eligibility is based on income criteria and insurance status
• Available to patients who are uninsured, underinsured, or have been denied coverage
• Patients apply through tevacares.org or by calling 1-877-237-4881
• Healthcare providers can submit applications on behalf of patients

Workflow tip: Keep PAP application forms readily available in your office. For patients who are denied insurance coverage after appeal, the PAP can be a bridge to continued treatment.

Coupon and Discount Cards

For patients paying cash or facing high copays that exceed the manufacturer card limits, third-party discount cards can sometimes help:

• GoodRx — May offer discount pricing at participating specialty pharmacies. Savings vary significantly by location and pharmacy.
• SingleCare — Another discount card option, though savings on specialty biologics are typically more limited than for generic medications.
• RxSaver and other aggregators — Worth checking, but specialty medication discounts through these platforms are inconsistent.

Reality check: Third-party coupon cards are most effective for generic oral medications. For a specialty biologic like Ajovy priced at $690+ per dose, these cards rarely bring the price to an affordable level on their own. They're best used as a supplement to the manufacturer savings card, not as a replacement.

For a comprehensive look at patient-facing savings options, see our guide on how to save money on Ajovy.

Generic Alternatives and Therapeutic Substitution

Generic/Biosimilar Status

As of early 2026, no generic or biosimilar version of Ajovy (Fremanezumab) is available. Patients who cannot afford the brand-name product need to explore the savings programs above or consider therapeutic alternatives.

Therapeutic Alternatives Within the CGRP Class

If Ajovy is not affordable or accessible for a patient, consider these CGRP-targeting alternatives:

• Aimovig (Erenumab) — Monthly subcutaneous autoinjector. Similar price point but different manufacturer savings program (Amgen). May be preferred by some insurance formularies.
• Emgality (Galcanezumab) — Monthly subcutaneous injection. Eli Lilly's savings program may offer better terms for some patients.
• Qulipta (Atogepant) — Daily oral tablet. For patients who prefer oral medication and whose insurance covers it more favorably. AbbVie offers its own savings program.
• Vyepti (Eptinezumab) — Quarterly IV infusion. Covered under medical benefit (Part B) rather than pharmacy benefit, which can mean different cost-sharing for Medicare patients.

Key consideration: Insurance formulary placement often determines which CGRP inhibitor is most affordable for a given patient. Check the patient's formulary before prescribing, and be prepared to pivot to the preferred agent if cost is a barrier.

Non-CGRP Alternatives

For patients who cannot access any CGRP inhibitor due to cost or insurance barriers, evidence-based generic alternatives include:

• Topiramate — Generic, widely available, typically $10 to $30/month
• Propranolol — Generic, typically $10 to $20/month
• Amitriptyline — Generic, typically $5 to $15/month
• Venlafaxine — Generic, typically $10 to $30/month

These are less targeted than CGRP inhibitors and carry more side effects, but they remain effective first-line preventives for many patients and cost a fraction of the price.

Building Cost Conversations into Your Workflow

The most effective cost intervention is the one that happens before the patient leaves your office. Here's how to systematically address medication costs:

1. Check Insurance Coverage Before Prescribing

Use your EHR's formulary check or contact the patient's insurer to verify:

• Is Ajovy covered on their formulary?
• What tier is it on?
• What prior authorization criteria apply?
• Is step therapy required, and has the patient already met those requirements?

2. Proactively Offer Savings Resources

Don't wait for the patient to ask about cost. At the point of prescribing:

• Provide the Ajovy Savings Card information (ajovy.com/savings)
• For uninsured patients, initiate the Teva Cares PAP application
• Mention that your office can help with prior authorization and appeals

3. Partner with Your Specialty Pharmacy

Specialty pharmacies often have benefits investigation teams that can:

• Verify insurance coverage and out-of-pocket costs before dispensing
• Enroll patients in the manufacturer savings card
• Identify alternative funding sources
• Flag potential issues before the patient encounters them

4. Document Step Therapy Failures Thoroughly

Many insurance denials for Ajovy stem from insufficient documentation of prior treatment failures. When a patient has tried and failed other preventives:

• Document the specific medication, dose, duration, and reason for discontinuation
• Include objective measures (migraine diary data, headache days per month)
• Note any intolerable side effects that led to discontinuation

Thorough documentation at the time of treatment — not retroactively at PA submission — makes the authorization process significantly smoother.

5. Have a Backup Plan

If the first-choice CGRP inhibitor is denied or unaffordable, know which alternative your patient's insurer prefers. Having a Plan B ready prevents treatment delays.

Provider Resources

Additional tools for your practice:

• Ajovy HCP site — ajovyhcp.com — prescribing information, dosing guides, and prior authorization support
• Teva Shared Solutions — 1-800-671-3674 — reimbursement support for providers
• Medfinder for Providers — medfinder.com/providers — help patients locate pharmacies with Ajovy in stock

Final Thoughts

Prescribing Ajovy is only half the battle. Ensuring your patients can actually afford and access it is what turns a prescription into a treatment outcome. By proactively offering savings resources, partnering with specialty pharmacies, and building cost conversations into your standard workflow, you can significantly improve fill rates and treatment adherence.

The tools exist — manufacturer savings cards, patient assistance programs, insurance navigation support. The key is making them part of your process, not an afterthought. Your patients with migraine deserve treatment that works — and the ability to actually use it.

Visit Medfinder for Providers to help your patients find Ajovy in stock near them.